Since diabetes leads to increased TNFα and decreased IGFBP-3, increased understanding of the interrelationship of TNFα and IGFBP-3 will likely lead to refined therapies that can promote IGFBP-3 actions, while inhibiting TNFα activities. Here, IGFBP3 is linked to diabetes mellitus.